Impact of OMEGA-3 fatty acid in patients undergoing hemodialysis: a systematic review and meta-analysis
Ahmed Jilani HB, Baig BM, Rasool A, Ibrahim M, Khalid A, Rizvi MS, Daniyal SM, Jalal AA, Arfan A, Samad ZA, Saad M, Rao H, Jalaluddin J, Jabarkhil R
BMC nephrology · 0 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-06-19 · BMC Nephrol · vol. 27 · número 1
- Editorial
- BioMed Central
- Citado
- 0 citas · más que el 36% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Dialysis and Renal Disease Management · Nutritional Studies and Diet
- Palabras clave
- omega-3 fatty acids, dietary supplementation, hemodialysis, cardiovascular mortality, all-cause mortality, myocardial infarction, vascular access complications, cardioprotection, end-stage renal disease
- MeSH
- humans, kidney failure, chronic, cardiovascular diseases, fatty acids, omega-3, renal dialysis, dietary supplements, randomized controlled trials as topic
14 autores
- Hafiz Bilal Ahmed🇵🇰Dow University of Health Sciences
- Burhan Mazhar Baig🇵🇰Dow University of Health Sciences
- Anas Rasool🇵🇰Dow University of Health Sciences
- Muhammad Ibrahim🇵🇰Dow University of Health Sciences
- Ayan Khalid🇵🇰Dow University of Health Sciences
- Muhammad Shaharyar Rizvi🇵🇰Dow University of Health Sciences
- Shaikh Muhammad Daniyal🇵🇰Dow University of Health Sciences
- Amna Amir Jalal🇵🇰Jinnah Sindh Medical University
- Alishba Arfan🇵🇰Dow University of Health Sciences
- Zaid Abdul Samad🇵🇰Dow University of Health Sciences
- Muhammad Saad🇵🇰Dow University of Health Sciences
- Hammad Rao
- Junaid Jalaluddin🇵🇰Jinnah Medical & Dental College
- Romal Jabarkhil
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Cardiovascular disease is the leading cause of death among patients undergoing hemodialysis, while effective preventive strategies remain limited. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated cardiovascular benefits in the general population. We evaluated the effects of n-3 PUFA supplementation in adults receiving hemodialysis.
Methods
PubMed, Embase, and CENTRAL were searched through November 2025 for randomized controlled trials (RCTs) comparing n-3 PUFAs versus placebo in adult hemodialysis patients. Data were pooled using a random-effects model and reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). Subgroup analyses were performed based on Diabetes, Hypertension, Age and Follow-up.
Results
n-3 PUFA supplementation did not significantly reduce all-cause mortality (RR = 0.93; 95% CI 0.80-1.08; p = 0.33). In contrast, cardiovascular mortality was significantly reduced (RR = 0.55; 95% CI 0.42-0.71; p < 0.001) along with fewer vascular access related events (RR = 0.83; 95% CI 0.73-0.95; p = 0.005). significant effects were observed for fatal or non-fatal MI (RR = 0.50; 95% CI 0.36-0.68; p < 0.001).
Conclusions
n-3 PUFA supplementation significantly reduces cardiovascular mortality, myocardial infarction, and vascular access events in hemodialysis patients without affecting all-cause mortality. While these findings support n-3 PUFAs as adjunctive cardioprotective therapy in this population, the concentration of evidence in a single large trial warrants cautious interpretation, and confirmation from further large RCTs remains necessary.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.